ABSTRACT The use of antimicrobials will be soon removed due to an increase of occurrence of antibiotic-resistant bacteria or ionophore-resistant Eimeria species in poultry farms and consumers' preference on drug-free chicken meats or eggs. Although dietary antimicrobials contributed to the growth and health of the chickens, we do not fully understand their interrelationship among antimicrobials, gut microbiota, and host immunity in poultry. In this review, we explored the current understanding on the effects of antimicrobials on gut microbiota and immune systems of chickens. Based on the published literatures, it is clear that antibiotics and antibiotic ionophores, when used singly or in combination could influence gut microbiota. However, antimicrobial effect on gut microbiota varied depending on the samples (e.g., gut locations, digesta vs. mucosa) used and among the experiments. It was noted that the digesta vs. the mucosa is the preferred sample with the results of no change, increase, or decrease in gut microbiota community. In future, the mucosa-associated bacteria should be targeted as they are known to closely interact with the host immune system and pathogen control. Although limited, dietary antimicrobials are known to modulate humoral and cell-mediated immunities. Ironically, the evidence is increasing that dietary antimicrobials may play an important role in triggering enteric disease such as gangrenous dermatitis, a devastating disease in poultry industry. Future work should be done to unravel our understanding on the complex interaction of host-pathogen-microbiotaantimicrobials in poultry.
INTRODUCTION
The human population is projected to grow to 9～10 billion by the year 2050 (Godfray et al., 2010) . As a consequence of the population explosion, food animal production would confront a new array of challenges. Among these are global food security, climate change, emerging infectious diseases, regulatory ban on use of antimicrobials, high-density production conditions, and waste management (Grasty, 1999; Turnpenny et al., 2001; Bohannon, 2004) . Approximately 71 million tons of poultry meats were produced worldwide in 2009 (USDA-FAS, 2009 ). In order to assure continuity in the supply of poultry food products, effective control measures against infectious diseases in the framework of environmental change are critical (Dekich, 1998) . In the United States, Clostridium-related diseases, such as gangrenous dermatitis (GD) and necrotic enteritis (NE), and coccidiosis are among the most important infectious diseases in chickens and turkeys (Shane, 2004a, b; Smith and Helm, 2008) .
Traditionally, antimicrobials, a combination of antibiotics and anticoccidial drugs are commonly practiced in food animal production. Recently, vaccination against coccidiosis plus antibiotics in diets has been increasingly implemented. Overall, these vaccination and medication practices are used as preventive measures on either pathogenic Eimeria spp. or growth depressing pathogenic and non-pathogenic bacteria, or both.
In-feed antimicrobials are well known to affect gut microbiota due to their apparent in vitro antimicrobial properties.
For example, Lu et al. (2006) observed that Lactobacillus acidophilus was the most abundant species in birds fed on a nonmedicated plain control diet, whereas L. crispatus represented the dominant Lactobacillus in birds fed a diet containing monensin at the concentration of 90 ppm using terminal restriction fragment length polymorphism (T-RFLP) analysis.
Additionally, a higher relative abundance of gram-negative bacteria (e.g., Proteobacteria and Bacteroides) was observed in the monensin-fed chickens and especially Clostridia, i.e., Clostridium irregularis and C. lituseburense were particularly Lee and Lillehoj : Antimicrobials, Gut Microbiota and Immunity in Chickens 156 dominant. In their following study (Lu et al., 2008) , gut microbiota of broiler chickens fed diet containing antibiotic growth promoters (bacitracin methylene disalicylate and virginiamycin; AGPs) was completely different from those seen in birds fed a non-medicated control diet, indicating that low levels of in-feed antimicrobials can substantially influence gut microbiota in broiler chickens.
In addition, the evidence is increasing that gut microbiota plays an important role in health, immunity and disease prevention (Dibner et al., 2008; Sekirov et al., 2008) . The published data (Turnbaugh et al., 2006; Caesar et al., 2010; Wlodarska and Finlay, 2010) supported the view that altered microbiota is linked to obesity, inflammatory bowel disease (IBD), atherosclerosis and cancer. It has been proposed that there is close interaction between altered microbiota by infeed antimicrobials and host susceptibility to pathogens (e.g., gangrenous dermatitis) in broiler chickens (Ritter 2006; Ritter et al., 2010) . In this sense, commonly used antimicrobials in poultry production will have definite impact on intestinal microbiota and host immunity. Recent developments on microbiota analysis techniques broaden our understanding on interrelation between host immunity and microbiota, and their association with disease. Especially, there is increasing evidence that low-level inclusion of antimicrobials, e.g., antibiotics, antibiotic-like coccidiostats and chemicals may render the host susceptible to the enteric disease such as Clostridium spp. The present review will discuss the current understanding on the effects of antimicrobials on gut microbiota and immune systems of chickens.
GUT MICROBIOTA AND IMMUNE

SYSTEM OF CHICKENS
At hatch, the alimentary tract and immune system of chicks is less well developed compared with mature birds (Lowenthal et al., 1994; Koenen et al., 2002) . Thus, broiler chicks at early ages are very susceptible to pathogenic bacteria, which can otherwise be protected by a healthy gut microbiota (Nurmi and Rantala, 1973) . It is well-known that a close relationship exists between the gastrointestinal tract (GIT) microflora and development and/or maintenance of a functional intestinal immune system (Salminen et al., 1998; Gabriel et al., 2006) . For example, germ-free mammals have a higher susceptibility to intestinal infections (O'Hara and Shanahan, 2006) and are unable to mount an effective antibody response until reestablishment of their gut microflora (Rhee et al., 2004) .
Similarly, germ-free chicks failed to trigger intestinal immune response to heat inactivated Escherichia coli antigen. The immunological maturity of the germ-free chicks was delayed due to the lack of the stimulation by the gut microbiota on antibody producing B-cells (Parry et al., 1977) .
At early ages, the gut microbiota of chicks is not well cha- Following hatching, chicken adaptive immunity requires at least three weeks for complete maturation and development Lee and Lillehoj : Antimicrobials, Gut (Cebra, 1999) .
EFFECT OF ANTIMICROBIALS ON GUT MICROBIOTA COMMUNITY
Recent development on molecular analytical tools on microbiota greatly enhanced our understanding on gut microbiota (Zoetendal et al., 2004) . was reported (Mountzouris et al., 2010) . In line with the result by Mountzouris et al. (2010) , Fairchild et al. (2005) studied the cecal microbiota community using T-RFLP analysis on 16S rRNA gene amplicons in 4-week-old broiler chickens that had been treated with oxytetracycline for 5 days. It was found that oral administration exhibited little effect on the cecal microbiota community at 2 days and 2 weeks after oxytetracycline treatment.
The bacteria can colonize both digesta in the lumen and the mucosa epithelium with its distinct microbiota. Gong et al. (2002) analyzed microbiota community on the mucosa and digesta of the ileum by T-RFLP with restriction enzymes such as AluI, HhaI, and MspI and found the heterogeneous bacterial population in the mucosa and digesta in the ileum.
In many studies, the digesta vs. the mucosa is the preferred sample with the results of no change, increase, or decrease in gut microbiota community by dietary antimicrobials. The influence of dietary antimicrobials on the mucosa-associated bacteria is relatively limited. Recently, Chee et al. (2010) have reported that antibiotic treatment affected the number of lactobacilli in digesta of the ileum, but not on the mucosa.
On the contrary, dietary antibiotics are known to alter the mucosa-associated bacteria by the DGGE analysis (Pedroso et al., 2006) . Wise and Siragusa (2007) sampled the mixed ileal luminal and mucosal materials from chickens raised under drug-free or conventional antibiotic regimes and analyzed them using quantitative real time PCR with group-specific 16s rRNA primer sets. They noticed that total domain bacteria 16S rRNA on DNA isolated from the mixed digesta/ mucosa-associated samples was not different in birds raised with or without AGP at days 7, 14 and 21. However, they found that populations of Enterobacteriaceae and Bifidobacterium spp. were significantly decreased in drug-fed chickens compared with those in drug-free chickens at days 7 and 21.
On the contrary, the most abundant classes in ileal community, Lactobacillus group was not altered at all ages by medication. Given that the mucosa-associated microbiota has been known to play a role in pathogen control and immune modulation (Gong et al., 2002) , future studies should be targeting on analyzing the mucosa-associated bacteria in relation to the responses to dietary antimicrobials. observed. However, with ND vaccination regime, IFN-γ production in Con-A-stimulated splenocytes was significantly elevated in antibiotic-treated chickens compared with the non-medicated control group. These two studies (Munir et al., 2007; Khalifeh et al., 2009 ) support the view that antimicrobials can enhance cell-mediated immunity in broiler chickens.
Intraepithelial lymphocytes (IELs) constitute the primary immune effector cells in the gut and play a critical role in eliciting protective immunity to enteric pathogens (Lillehoj et al., 2004; Lillehoj and Trout, 1996) . Stimulation or suppression of specific IEL subsets by in-feed antimicrobials will likely contribute to increased or decreased host resistance to enteric pathogens that would cause clinical disease. Given the earlier observations that gut microbiota can influence the development of immune system, Arias and Koutsos (2006) investigated whether antibiotics would affect lymphocyte populations in broiler chickens raised in re-used or fresh litters.
Lymphocytes in lamina propria and IELs were counted on hematoxylin and eosin stained sections from duodenum, jejunum and ileum. Unfortunately, they did not use the sensitive flow cytometer assay targeting specific lymphocyte population. Duodenal, but not jejunal and ileal, lamina propria lymphocytes were significantly low in antibiotic-fed chicks compared with the non-medicated control group when they were raised on the reused litter. For IELs, antibiotic treatment did not affect IEL numbers when the birds were raised on the Although not discussed in this review, the use of AGPs and anticoccidials in the future poultry industry will be phased out in many countries due to emergence of drug-resistance strains and consumers' preference for drug-free meats. Since the EU's ban on AGPs in 2006, this trend will expect to spread to the rest of the world. For example, Korean Authority decided to remove AGPs from animal feeds, and only 9 anticoccidials (salinomycin, monensin, lasalocid, narasin, maduramicin, semduramicin, clopidol, fenbendazole, and diclazuril) will be used. This Act (Control of Livestock and Fish Feed Act) will be effective from July 2011. In USA, AGPs and anticoccidials are widely used in poultry feeds. However, U.S. Food and Drug Administration has been trying to persuade pharmaceutical companies to voluntarily stop providing antibiotics to promote livestock growth. In any event, without AGPs, it can be readily expected that NE, the most important infectious diseases in the current poultry production system globally with estimated annual economic loss of more than $ 2 billion, will be re-emerged as a significant problem.
Thus, it is certain that we will continue to face the challenges in identifying alternatives that can effectively replace AGPs.
Although the searching for the alternatives to AGPs is not the scope of the current review, the integrated research system involving diverse scientists in the field of immunology, genomics, molecular biology, proteomics, parasitology, and nutrition should be applied to gain better knowledge in developing novel alternatives to AGPs.
